Former Director Files Intent to Sell $640K in Shares
ABEO sits 58% above its 52-week low of $4.
Summary
A former director of Abeona Therapeutics has filed a Form 144 to sell approximately $640,771 worth of common stock, adding to recent insider selling activity.
Key Events · Ownership and Investor Activity · ABEO
-
Former Director Files Intent to Sell
Christine Silverstein, a former Director, has filed a Form 144 indicating her intent to sell 102,180 shares of Abeona Therapeutics common stock.
-
Proposed Sale Value
The shares intended for sale have an approximate market value of $640,771.00 based on the current stock price.
-
Shares from Equity Compensation
The shares to be sold were acquired through various Restricted Stock Awards (RSAs) between May 2020 and June 2026 as equity compensation.
-
Recent Insider Selling Context
This filing follows a period of net insider distribution, with over $863,898 in open-market sales by insiders over the last 90 days.
Analysis · ABEO · Life Sciences
A former director has filed a Form 144 indicating intent to sell 102,180 shares of common stock, valued at approximately $640,771. These shares were acquired through equity compensation. This proposed sale adds to the existing trend of insider distribution, with over $860,000 in net insider sales reported in the last 90 days. While from a former director, the size of the intended sale is notable and contributes to a negative sentiment regarding insider confidence.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.4% of the 1431 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABEO was trading at $6.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $359.6M. The 52-week trading range was $4.00 to $7.54. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.